Chronic Obstructive Pulmonary Disease Exacerbations
Herausgeber: Wedzicha, Jadwiga A; Martinez, Fernando J
Chronic Obstructive Pulmonary Disease Exacerbations
Herausgeber: Wedzicha, Jadwiga A; Martinez, Fernando J
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Chronic Obstructive Pulmonary Disease Exacerbations covers the definition, diagnosis, epidemiology, mechanisms, and treatment associated with COPD exacerbations. This text also addresses imaging and how it plays a pivotal role in the diagnosis and study of exacerbations.
Andere Kunden interessierten sich auch für
- Genetics of Asthma and Chronic Obstructive Pulmonary Disease89,99 €
- Ronaldo Collo GoPulmonary Disease Examination and Board Review103,99 €
- Interventional Pulmonary Medicine89,99 €
- Pulmonary Hypertension90,99 €
- Kevin BrownOxford American Handbook of Pulmonary Medicine83,99 €
- Juzar AliPulmonary Pathophysiology: A Clinical Approach, Third Edition73,99 €
- Pulmonary Tuberculosis: A Handbook For Students And Practitioners23,99 €
-
-
-
Chronic Obstructive Pulmonary Disease Exacerbations covers the definition, diagnosis, epidemiology, mechanisms, and treatment associated with COPD exacerbations. This text also addresses imaging and how it plays a pivotal role in the diagnosis and study of exacerbations.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis Ltd (Sales)
- Seitenzahl: 476
- Erscheinungstermin: 10. September 2018
- Englisch
- Abmessung: 229mm x 152mm x 24mm
- Gewicht: 630g
- ISBN-13: 9781138372450
- ISBN-10: 1138372455
- Artikelnr.: 55103600
- Verlag: Taylor & Francis Ltd (Sales)
- Seitenzahl: 476
- Erscheinungstermin: 10. September 2018
- Englisch
- Abmessung: 229mm x 152mm x 24mm
- Gewicht: 630g
- ISBN-13: 9781138372450
- ISBN-10: 1138372455
- Artikelnr.: 55103600
JADWIGA A. WEDZICHA is Professor of Respiratory Medicine at the University College London and Honorary Consultant Physician, Royal Free Hospital NHS Trust, London, UK. She received her M.D. from the University of London, London, UK. Dr. Wedzicha has a major interest in the causes, mechanisms, and impact of COPD exacerbations and has published extensively on this topic. She also is an expert on home oxygen therapy and non-invasive ventilation in COPD patients. Dr. Wedzicha has chaired the British Thoracic Society (BTS) working group on home oxygen therapy, is currently chairing the BTS Home Oxygen Guidelines Group, and is a member of the Department of Health's External Stakeholders Advisory Group for the Home Oxygen Service. She was a member of the Guideline Development Group for the NICE COPD guidelines and the External Reference Group (ERG) of the COPD National Service Framework (NSF). Dr. Wedzicha directs an active internationally recognized research group into aspects of COPD exacerbations with major grant funding. She is currently Editor-in-Chief of the respiratory journal Thorax, a member of the British Medical Journal advisory board, and an editorial board member for a number of international journals. FERNANDO J. MARTINEZ is Medical Director of Pulmonary Diagnostic Services; Pulmonary Director of the Cough/Dyspnea Clinic; Associate Director of Bronchoscopy Service; Director of the Lung Volume Reduction Program; Professor of Pulmonary and Critical Care Medicine; and Co-Medical Director of the Lung Transplantation Program, the University of Michigan Health System, Ann Arbor, Michigan, USA. Dr. Martinez received his M.D. from the University of Florida School of Medicine, Gainesville, Florida, USA. From 2002 to the present, he has been named on both the national and Midwest "Best Doctors in America" lists, in addition to "Metro Detroit's Best Doctors" list. Dr. Martinez is an active member of several professional organizations, including the American College of Chest Physicians, the American Thoracic Society, and the American Association of Cardiovascular and Pulmonary Rehabilitation. He is Associate Editor of the American Journal of Respiratory and Critical Care Medicine, and he serves on the editorial and review boards of several other journal publications. Dr. Martinez is an accomplished author/contributor and invited lecturer, and has received numerous grants to research respiratory health and disease.
Part I: Introduction. Definitions and severity of COPD exacerbations.
Epidemiology of COPD exacerbations. Differential diagnosis of COPD
exacerbations. PART II: Mechanisms and Pathophysiology. Symptom changes at
exacerbations. Airway pathology at exacerbations. Airway and systemic
inflammatory markers at exacerbation. Physiological changes at
exacerbations. Systemic consequences of COPD exacerbations. Mechanisms of
respiratory failure at exacerbation. Role of respiratory viral infection at
exacerbation. Do airway bacteria cause COPD exacerbations? Interactions of
airway pathogens and inflammatory processes. Role of co-morbidity at COPD
exacerbations. Environmental causes of exacerbations. Mechanisms and
pathophysiological changes in alpha-1 AT deficiency exacerbations.
Experimental models of COPD exacerbations. Comparison of asthma and COPD
exacerbations. Part III: Impact of Exacerbations. Exacerbations and health
status. Risk factors for hospital admission. Effect of exacerbations on
disease progression and mortality. Health economic consequences of COPD
exacerbations. Part IV: Management of the Acute Exacerbation. Use of
bronchodilators and mucolytics at COPD exacerbations. Corticosteroids in
the management of acute exacerbations. Antibiotic therapy at COPD
exacerbations. Non invasive ventilatory support. Invasive ventilation and
weaning at COPD exacerbation. Oxygen therapy at exacerbations. End of life
issues and COPD exacerbations. Novel models of care for COPD exacerbations.
Physiotherapy airway clearance at exacerbation. COPD exacerbation and
pulmonary rehabilitation. Part V: Prevention of COPD Exacerbation.
Pharmacological prevention of COPD exacerbations. Early intervention and
self-management in exacerbation prevention. Immunological interventions.
Home mechanical ventilation and oxygen therapy. Part VI: Issues for Studies
of COPD Exacerbations. Design of trials for COPD exacerbations. Statistical
considerations for COPD exacerbation trials. Future development in COPD
exacerbations.
Epidemiology of COPD exacerbations. Differential diagnosis of COPD
exacerbations. PART II: Mechanisms and Pathophysiology. Symptom changes at
exacerbations. Airway pathology at exacerbations. Airway and systemic
inflammatory markers at exacerbation. Physiological changes at
exacerbations. Systemic consequences of COPD exacerbations. Mechanisms of
respiratory failure at exacerbation. Role of respiratory viral infection at
exacerbation. Do airway bacteria cause COPD exacerbations? Interactions of
airway pathogens and inflammatory processes. Role of co-morbidity at COPD
exacerbations. Environmental causes of exacerbations. Mechanisms and
pathophysiological changes in alpha-1 AT deficiency exacerbations.
Experimental models of COPD exacerbations. Comparison of asthma and COPD
exacerbations. Part III: Impact of Exacerbations. Exacerbations and health
status. Risk factors for hospital admission. Effect of exacerbations on
disease progression and mortality. Health economic consequences of COPD
exacerbations. Part IV: Management of the Acute Exacerbation. Use of
bronchodilators and mucolytics at COPD exacerbations. Corticosteroids in
the management of acute exacerbations. Antibiotic therapy at COPD
exacerbations. Non invasive ventilatory support. Invasive ventilation and
weaning at COPD exacerbation. Oxygen therapy at exacerbations. End of life
issues and COPD exacerbations. Novel models of care for COPD exacerbations.
Physiotherapy airway clearance at exacerbation. COPD exacerbation and
pulmonary rehabilitation. Part V: Prevention of COPD Exacerbation.
Pharmacological prevention of COPD exacerbations. Early intervention and
self-management in exacerbation prevention. Immunological interventions.
Home mechanical ventilation and oxygen therapy. Part VI: Issues for Studies
of COPD Exacerbations. Design of trials for COPD exacerbations. Statistical
considerations for COPD exacerbation trials. Future development in COPD
exacerbations.
Part I: Introduction. Definitions and severity of COPD exacerbations.
Epidemiology of COPD exacerbations. Differential diagnosis of COPD
exacerbations. PART II: Mechanisms and Pathophysiology. Symptom changes at
exacerbations. Airway pathology at exacerbations. Airway and systemic
inflammatory markers at exacerbation. Physiological changes at
exacerbations. Systemic consequences of COPD exacerbations. Mechanisms of
respiratory failure at exacerbation. Role of respiratory viral infection at
exacerbation. Do airway bacteria cause COPD exacerbations? Interactions of
airway pathogens and inflammatory processes. Role of co-morbidity at COPD
exacerbations. Environmental causes of exacerbations. Mechanisms and
pathophysiological changes in alpha-1 AT deficiency exacerbations.
Experimental models of COPD exacerbations. Comparison of asthma and COPD
exacerbations. Part III: Impact of Exacerbations. Exacerbations and health
status. Risk factors for hospital admission. Effect of exacerbations on
disease progression and mortality. Health economic consequences of COPD
exacerbations. Part IV: Management of the Acute Exacerbation. Use of
bronchodilators and mucolytics at COPD exacerbations. Corticosteroids in
the management of acute exacerbations. Antibiotic therapy at COPD
exacerbations. Non invasive ventilatory support. Invasive ventilation and
weaning at COPD exacerbation. Oxygen therapy at exacerbations. End of life
issues and COPD exacerbations. Novel models of care for COPD exacerbations.
Physiotherapy airway clearance at exacerbation. COPD exacerbation and
pulmonary rehabilitation. Part V: Prevention of COPD Exacerbation.
Pharmacological prevention of COPD exacerbations. Early intervention and
self-management in exacerbation prevention. Immunological interventions.
Home mechanical ventilation and oxygen therapy. Part VI: Issues for Studies
of COPD Exacerbations. Design of trials for COPD exacerbations. Statistical
considerations for COPD exacerbation trials. Future development in COPD
exacerbations.
Epidemiology of COPD exacerbations. Differential diagnosis of COPD
exacerbations. PART II: Mechanisms and Pathophysiology. Symptom changes at
exacerbations. Airway pathology at exacerbations. Airway and systemic
inflammatory markers at exacerbation. Physiological changes at
exacerbations. Systemic consequences of COPD exacerbations. Mechanisms of
respiratory failure at exacerbation. Role of respiratory viral infection at
exacerbation. Do airway bacteria cause COPD exacerbations? Interactions of
airway pathogens and inflammatory processes. Role of co-morbidity at COPD
exacerbations. Environmental causes of exacerbations. Mechanisms and
pathophysiological changes in alpha-1 AT deficiency exacerbations.
Experimental models of COPD exacerbations. Comparison of asthma and COPD
exacerbations. Part III: Impact of Exacerbations. Exacerbations and health
status. Risk factors for hospital admission. Effect of exacerbations on
disease progression and mortality. Health economic consequences of COPD
exacerbations. Part IV: Management of the Acute Exacerbation. Use of
bronchodilators and mucolytics at COPD exacerbations. Corticosteroids in
the management of acute exacerbations. Antibiotic therapy at COPD
exacerbations. Non invasive ventilatory support. Invasive ventilation and
weaning at COPD exacerbation. Oxygen therapy at exacerbations. End of life
issues and COPD exacerbations. Novel models of care for COPD exacerbations.
Physiotherapy airway clearance at exacerbation. COPD exacerbation and
pulmonary rehabilitation. Part V: Prevention of COPD Exacerbation.
Pharmacological prevention of COPD exacerbations. Early intervention and
self-management in exacerbation prevention. Immunological interventions.
Home mechanical ventilation and oxygen therapy. Part VI: Issues for Studies
of COPD Exacerbations. Design of trials for COPD exacerbations. Statistical
considerations for COPD exacerbation trials. Future development in COPD
exacerbations.